These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 26249340)

  • 1. Structural evidence for asymmetric ligand binding to transthyretin.
    Cianci M; Folli C; Zonta F; Florio P; Berni R; Zanotti G
    Acta Crystallogr D Biol Crystallogr; 2015 Aug; 71(Pt 8):1582-92. PubMed ID: 26249340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transthyretin Binding Heterogeneity and Anti-amyloidogenic Activity of Natural Polyphenols and Their Metabolites.
    Florio P; Folli C; Cianci M; Del Rio D; Zanotti G; Berni R
    J Biol Chem; 2015 Dec; 290(50):29769-80. PubMed ID: 26468275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural evidence for native state stabilization of a conformationally labile amyloidogenic transthyretin variant by fibrillogenesis inhibitors.
    Zanotti G; Cendron L; Folli C; Florio P; Imbimbo BP; Berni R
    FEBS Lett; 2013 Aug; 587(15):2325-31. PubMed ID: 23792159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crystallographic study of novel transthyretin ligands exhibiting negative-cooperativity between two thyroxine binding sites.
    Tomar D; Khan T; Singh RR; Mishra S; Gupta S; Surolia A; Salunke DM
    PLoS One; 2012; 7(9):e43522. PubMed ID: 22973437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new crystal form of human transthyretin obtained with a curcumin derived ligand.
    Polsinelli I; Nencetti S; Shepard W; Ciccone L; Orlandini E; Stura EA
    J Struct Biol; 2016 Apr; 194(1):8-17. PubMed ID: 26796656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repurposing Benzbromarone for Familial Amyloid Polyneuropathy: A New Transthyretin Tetramer Stabilizer.
    Cotrina EY; Oliveira Â; Leite JP; Llop J; Gales L; Quintana J; Cardoso I; Arsequell G
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32998442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and characterization of potent bivalent amyloidosis inhibitors that bind prior to transthyretin tetramerization.
    Green NS; Palaninathan SK; Sacchettini JC; Kelly JW
    J Am Chem Soc; 2003 Nov; 125(44):13404-14. PubMed ID: 14583036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conserved water mediated H-bonding dynamics of Ser117 and Thr119 residues in human transthyretin-thyroxin complexation: inhibitor modeling study through docking and molecular dynamics simulation.
    Banerjee A; Bairagya HR; Mukhopadhyay BP; Nandi TK; Mishra DK
    J Mol Graph Model; 2013 Jul; 44():70-80. PubMed ID: 23732306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conformational differences between the wild type and V30M mutant transthyretin modulate its binding to genistein: implications to tetramer stability and ligand-binding.
    Trivella DB; Bleicher L; Palmieri Lde C; Wiggers HJ; Montanari CA; Kelly JW; Lima LM; Foguel D; Polikarpov I
    J Struct Biol; 2010 Jun; 170(3):522-31. PubMed ID: 20211733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the effect of mutations and ligand binding on transthyretin homotetramer dynamics.
    Saldaño TE; Zanotti G; Parisi G; Fernandez-Alberti S
    PLoS One; 2017; 12(7):e0181019. PubMed ID: 28704493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetic stabilization of an oligomeric protein by a single ligand binding event.
    Wiseman RL; Johnson SM; Kelker MS; Foss T; Wilson IA; Kelly JW
    J Am Chem Soc; 2005 Apr; 127(15):5540-51. PubMed ID: 15826192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nearly 200 X-ray crystal structures of transthyretin: what do they tell us about this protein and the design of drugs for TTR amyloidoses?
    Palaninathan SK
    Curr Med Chem; 2012; 19(15):2324-42. PubMed ID: 22471981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Semi-quantitative models for identifying potent and selective transthyretin amyloidogenesis inhibitors.
    Connelly S; Mortenson DE; Choi S; Wilson IA; Powers ET; Kelly JW; Johnson SM
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3441-3449. PubMed ID: 28625364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure of a new polymorphic monoclinic form of human transthyretin at 3 A resolution reveals a mixed complex between unliganded and T4-bound tetramers of TTR.
    Wojtczak A; Neumann P; Cody V
    Acta Crystallogr D Biol Crystallogr; 2001 Jul; 57(Pt 7):957-67. PubMed ID: 11418763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Binding of a Pyrene-Based Fluorescent Amyloid Ligand to Transthyretin: A Combined Crystallographic and Molecular Dynamics Study.
    Thi Minh NN; Begum A; Zhang J; Leira P; Todarwal Y; Linares M; Norman P; Derbyshire D; von Castelmur E; Lindgren M; Hammarström P; König C
    J Phys Chem B; 2023 Aug; 127(30):6628-6635. PubMed ID: 37477604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of the glutamic acid 54 residue in transthyretin stability and thyroxine binding.
    Miyata M; Sato T; Mizuguchi M; Nakamura T; Ikemizu S; Nabeshima Y; Susuki S; Suwa Y; Morioka H; Ando Y; Suico MA; Shuto T; Koga T; Yamagata Y; Kai H
    Biochemistry; 2010 Jan; 49(1):114-23. PubMed ID: 19950966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crown Ethers as Transthyretin Amyloidogenesis Inhibitors.
    Yokoyama T; Mizuguchi M
    J Med Chem; 2019 Feb; 62(4):2076-2082. PubMed ID: 30688456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural and dynamics evidence for scaffold asymmetric flexibility of the human transthyretin tetramer.
    Zanotti G; Vallese F; Ferrari A; Menozzi I; Saldaño TE; Berto P; Fernandez-Alberti S; Berni R
    PLoS One; 2017; 12(12):e0187716. PubMed ID: 29240759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enthalpic Forces Correlate with the Selectivity of Transthyretin-Stabilizing Ligands in Human Plasma.
    Iakovleva I; Brännström K; Nilsson L; Gharibyan AL; Begum A; Anan I; Walfridsson M; Sauer-Eriksson AE; Olofsson A
    J Med Chem; 2015 Aug; 58(16):6507-15. PubMed ID: 26214366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses.
    Johnson SM; Wiseman RL; Sekijima Y; Green NS; Adamski-Werner SL; Kelly JW
    Acc Chem Res; 2005 Dec; 38(12):911-21. PubMed ID: 16359163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.